A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
Phase of Trial: Phase I/II
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs SB-BCLmR-HSPC (Primary) ; Busulfan; Plerixafor
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bioverativ
- 05 Aug 2019 Planned End Date changed from 1 Mar 2022 to 1 Sep 2022.
- 05 Aug 2019 Planned primary completion date changed from 1 Mar 2022 to 1 Sep 2022.
- 08 Jan 2019 Planned End Date changed from 1 Sep 2022 to 1 Mar 2022.